Pipeline Progress And Data ExpectationsProgress in the company's pipeline remains on track, with significant data expected in the upcoming years.
Stock Target Price IncreaseThe target price for Palvella Therapeutics, Inc. has been increased from $39 to $53.
Therapeutic Potential Of QTORIN RapamycinQTORIN rapamycin's therapeutic profile may position it as the standard of care first-line treatment for both Microcystic Lymphatic Malformation and Cutaneous Venous Malformation.